Antibody Name
|
Concentration (μg/ml)
|
Target Epitope
|
Cell line
|
ADE Measurement
|
Enhancement Strength
|
---|
31.3F01 [11]
|
0.4
|
Unknown
|
U937
|
Flow cytometry
|
48x
|
1.6D [13]
|
20
|
FLE
|
K562
|
qRT-PCR
|
140x
|
D11C [13]
|
20
|
FLE
|
K562
|
qRT-PCR
|
275x
|
ZKA3 [14]*
|
1
|
EDI/II
|
K562
|
Flow cytometry
|
~75x
|
ZKA78 [14]*
|
1
|
EDI/II
|
K562
|
Flow cytometry
|
~60x
|
DV82 [14]
|
1
|
EDI/II
|
K562
|
Flow cytometry
|
~16x
|
753(3) C10 [15]
|
0.1nM**
|
EDE1
|
U937
|
Focus forming assay
|
~80x
|
747(4) A11 [15]
|
1nM**
|
EDE2
|
U937
|
Focus forming assay
|
~90x
|
750-2C5 [15]
|
1nM**
|
FLE
|
U937
|
Focus forming assay
|
~60x
|
- qRT-PCR quantitative reverse transcription polymerase chain reaction
- * = hmAbs taken from ZIKV-infected donors and tested for enhancement of DENV infection
- ** = Molar mass not quoted in paper so unable to convert to μg/ml
- ~ = Approximation as values read from graph